SHAPED-AU

Not yet recruiting

Semaglutide Health Outcomes and Patient Adherence in Australia

Semaglutide Health Outcomes and Patient Adherence on Digital Health Platforms in Australia (SHAPED-AU)

Lead sponsor

Novo Nordisk A/S

Asset

Semaglutide

GLP-1 agonist

Listed sites

Recruiting sites

Estimated enrollment

10,000

Study population

Obesity / overweight

Eligibility highlights

•BMI ≥27

Primary endpoint

•Body weight

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07881770

Org study IDNN9536-8871

Timeline

Milestones

Study start2026-10-13estimated

Study first posted2026-10-19actual

Last update posted2026-10-19actual

Primary completion2028-02-28estimated

Study completion2028-02-28estimated

Assets

Investigational agents

Semaglutide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

This study will recruit individuals who are receiving semaglutide for the management of overweight or obesity and who are enrolled in one of the Eucalyptus Digital Weight Loss Service (DWLS) programmes.

Inclusion criteria

•Willing and able to provide informed consent

•Greater than or equal to (>=) 18 years of age at time of informed consent

•Body Mass Index (BMI) >= 27 kg/m2 and have >= 1 excess weight-related comorbidity OR BMI >= 30 kg/m2

•Eligible to be prescribed semaglutide for the management of overweight or obesity

•Have provided at least one weight measurement within 30 days of index date

•Enrolled in existing Eucalyptus DWLS programme.

Exclusion criteria

•Presence of a documented refusal to participate in research.

•Previous reported use of GLP-1 RA in the 3-month period before index date.

•Are currently taking another obesity medication i.e. medication indicated for weight management treatment.

•Any prior irreversible bariatric surgery for weight management

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

2 endpoints

Primary/protocol endpoint

Absolute change in body weight from baseline

Time frame:12 months (365 days ±14 days)

change from baseline, improvement

Primary/protocol endpoint

Percentage change in body weight from baseline

Time frame:12 months (365 days ±14 days)

percent change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateNovember 5, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.